Remodelling of the heart in DOCA-salt hypertensive rats by propranolol and by an alpha-2 agonist, rilmenidine.
The effects of rilmenidine [(N-dicyclopropylmethyl) amino-2-oxazoline; S 3341], an alpha 2 agonist, on the hypertensive rat heart have been compared with those of propranolol, using a model of deoxycorticosterone acetate (DOCA)-salt hypertension. One week after nephrectomy and initial treatment with DOCA-salt, which was continued for an additional 7 weeks, the two drugs were added to the rats drinking water at a concentration of 10 mg/kg per day for rilmenidine and 15 mg/kg per day for propranolol. Both drugs had a slight and similarly significant antihypertensive effect at their respective concentrations [systolic blood pressure in controls, 141 +/- 15 mmHg (n = 20); after DOCA-salt, 209 +/- 22 mmHg (n = 24); after propranolol, 182 +/- 19 mmHg (n = 20, P less than 0.01); after rilmenidine, 192 +/- 15 mmHg (n = 19, P less than 0.05)]. They also lowered the systolic blood pressure x frequency product (P less than 0.001). Propranolol, but not rilmenidine, significantly reduced the left ventricular weight: body weight ratio [in controls, 2.00 +/- 0.2 mg/g; after DOCA-salt, 3.04 +/- 0.5 mg/g; after propranolol, 2.67 +/- 0.4 mg/g (P less than 0.05); after rilmenidine, 3.13 +/- 0.6 mg/g (P = NS)]. However, both propranolol and rilmenidine reduced left ventricular weight [in controls, 676 +/- 57 mg; after DOCA-salt, 827 +/- 114 mg; after propranolol, 732 +/- 108 mg (P less than 0.01); after rilmenidine, 760 +/- 100 mg (P less than 0.05)].(ABSTRACT TRUNCATED AT 250 WORDS)
Callens-el Amrani
F
F
Unité 127 de l'Institut National de la Santé et de la Recherche Médical, Hôpital Lariboisière, Paris, France.
Paolaggi
F
F
Swynghedauw
B
B
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use*; D000704:Analysis of Variance; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure; D006332:Cardiomegaly / Q000503:physiopathology; D003900:Desoxycorticosterone; D004195:Disease Models, Animal; D006321:Heart / Q000033:anatomy & histology / Q000187:drug effects / Q000503:physiopathology; D006339:Heart Rate; D006973:Hypertension / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D010080:Oxazoles / Q000627:therapeutic use*; D011433:Propranolol / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D000077769:Rilmenidine; D012965:Sodium Chloride
D000316:Adrenergic alpha-Agonists; D000959:Antihypertensive Agents; D010080:Oxazoles; D003900:Desoxycorticosterone; D012965:Sodium Chloride; D011433:Propranolol; D000077769:Rilmenidine